News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Ambrilia Biopharma Inc. Announces Third Quarter 2007 Results and Provides Update on its Development Program
November 14, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MONTREAL, QUEBEC--(Marketwire - November 14, 2007) - Ambrilia Biopharma Inc. (TSX: AMB) announced today the third quarter 2007 financial results and provided an update on its development program.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Layoff Tracker
Sionna says good-bye to 46% of staffers, including exec
September 16, 2026
·
93 min read
·
BioSpace Editorial Staff
Funding
Sling catches $123M series C for thyroid eye disease pill
September 16, 2026
·
2 min read
·
Tristan Manalac
FDA
FDA hears input on psychedelics, PDUFA, lung cancer’s next-gen therapies boost survival
September 16, 2026
·
1 min read
·
Jef Akst
Deals
GSK bags Chimagen’s trispecific T cell engager in deal worth up to $750M
September 15, 2026
·
2 min read
·
Gabrielle Masson